Loading...
Market
J&J Global Immunology Market Ranking by 2025
2
Resolution / Starting Odds
Top 3 • 33%
Top 5 • 33%
Top 10 • 34%
Market research reports or industry analysis
Story
Johnson & Johnson to Acquire Proteologix for $850 Million to Boost Immunology Portfolio
May 16, 2024, 12:25 PM
On May 16, Johnson & Johnson announced that it will acquire privately held, stealthy start-up Proteologix for $850 million in cash, with the potential for additional milestone payments. The acquisition aims to bolster Johnson & Johnson's position in the treatment of atopic dermatitis and other immunologic disorders. Proteologix brings a pipeline of bispecific antibodies, including a phase 1-ready TSLP/IL13 bispecific and experimental treatments for asthma and atopic dermatitis. This acquisition, which includes dual-targeting antibody drugs, is part of Johnson & Johnson's strategy to expand its immunology portfolio and is the latest M&A deal involving molecules addressing TSLP.
View original story
Similar markets
Significant increase in revenue • 25%
Moderate increase in revenue • 25%
No significant impact on revenue • 25%
Decrease in revenue • 25%
Significant gain in market share • 33%
Moderate gain in market share • 34%
No significant change in market share • 33%
Top 10 globally • 25%
Top 50 globally • 25%
No significant change • 25%
Loses market position • 25%
Less than 10% • 25%
10% to 25% • 25%
26% to 50% • 25%
More than 50% • 25%
Significant increase in J&J stock price • 33%
Moderate increase in J&J stock price • 34%
No significant change in J&J stock price • 33%
Below 20% market share • 33%
20-40% market share • 34%
Above 40% market share • 33%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Oncology • 25%
Biopharmaceuticals • 25%
Rare diseases • 25%
Other • 25%
Biocon's biosimilar dominates • 33%
Biogen's biosimilar dominates • 33%
Equal market share between Biocon and Biogen • 34%
Adopted in 1-5 countries • 25%
Adopted in 6-10 countries • 25%
Adopted in 11-20 countries • 25%
Adopted in 21 or more countries • 25%
No significant impact • 25%
Moderate decrease in market size • 25%
Significant decrease in market size • 25%
Increase in market size • 25%